|
| related topics |
| {product, candidate, development} |
| {stock, price, share} |
| {product, liability, claim} |
| {interest, director, officer} |
| {control, financial, internal} |
| {property, intellectual, protect} |
| {tax, income, asset} |
| {financial, litigation, operation} |
| {debt, indebtedness, cash} |
| {operation, international, foreign} |
| {capital, credit, financial} |
| {acquisition, growth, future} |
| {customer, product, revenue} |
|
|
We may not be able to continue to operate our business if we are unable to attract additional operating capital.
Our independent registered public accounting firm has included a going concern paragraph in their report on our financial statements.
Our current products cannot be sold in certain countries if we do not obtain and maintain regulatory approval.
Our future prospects will be negatively impacted if we are unsuccessful in pending litigation over the CIT technology.
The value of intangible assets may not be equal to their carrying values.
If our intellectual property positions are challenged, invalidated or circumvented, or if we fail to prevail in future intellectual property litigation, our business could be adversely affected.
We face substantial competition, and others may discover, develop, acquire or commercialize products before or more successfully than we do.
We have limited sales of the ONKO-SURE tm
test kit and are reliant on our distributors for sales of our products.
We have a significant amount of relatively short term indebtedness that is in default and we may be unable to satisfy our obligations to pay interest and principal thereon when due.
We are subject to risks associated with our foreign distributors.
We do not intend to pay dividends on our common stock in the foreseeable future.
If we fail to comply with the rules under the Sarbanes-Oxley Act related to accounting controls and procedures or if the material weaknesses or other deficiencies in our internal accounting procedures are not remediated, our stock price could decline significantly.
Our stock price is volatile, which could adversely affect your investment.
Our stock price and financing may be adversely affected by outstanding warrants and convertible securities.
We have limited product liability insurance.
Full 10-K form ▸
|
|
| related documents |
| 1017491--3/26/2007--NEXMED_INC |
| 874443--3/22/2007--GENELABS_TECHNOLOGIES_INC_/CA |
| 849636--4/8/2010--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 1298700--11/17/2008--Verdant_Technology_CORP |
| 1298700--11/17/2008--Verdant_Technology_CORP |
| 1298700--4/15/2009--Verdant_Technology_CORP |
| 71478--3/28/2008--LIPID_SCIENCES_INC/ |
| 71478--3/15/2006--LIPID_SCIENCES_INC/ |
| 1041024--3/16/2009--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
| 849636--3/16/2006--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 849636--3/15/2007--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 1298700--11/17/2008--Verdant_Technology_CORP |
| 838879--3/31/2008--AMDL_INC |
| 1030839--2/13/2007--Synovics_Pharmaceuticals |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
| 1017491--3/16/2006--NEXMED_INC |
| 1041024--3/12/2010--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
| 1016546--3/13/2007--ALTAIR_NANOTECHNOLOGIES_INC |
| 1041024--3/24/2008--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
| 1096560--4/2/2007--SULPHCO_INC |
| 858803--12/17/2008--AVANIR_PHARMACEUTICALS |
| 38074--6/14/2006--FOREST_LABORATORIES_INC |
| 14272--2/22/2008--BRISTOL_MYERS_SQUIBB_CO |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 817785--3/28/2006--IMMUNE_RESPONSE_CORP |
| 1072379--4/18/2006--NORTHWEST_BIOTHERAPEUTICS_INC |
| 1072379--4/17/2007--NORTHWEST_BIOTHERAPEUTICS_INC |
| 891288--3/18/2008--QUESTCOR_PHARMACEUTICALS_INC |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 926617--4/2/2007--CIPHERGEN_BIOSYSTEMS_INC |
|